Experts examine investments in stem cell field

12/30/2009 | Wall Street Journal, The

Investors are often reluctant to fund stem cell startups and may not be aware of the differences between embryonic and adult stem cells and their potential uses as therapies, said Hadar Ron of Israel HealthCare Ventures and Yael Margolin, Gamida Cell's CEO. In this interview, Margolin said she believes that the Obama administration's decision to ease funding restrictions on embryonic stem cell research will renew investors' interest in the field.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park